Wild-type (senile) amyloidosis natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
Line 43: | Line 43: | ||
* Wild-type (senile) amyloidosis is most commonly complicated by [[Heart failure with reduced ejection fraction|heart failure with reduced ejection fraction (HFrEF)]].<ref name=":0" /> | * Wild-type (senile) amyloidosis is most commonly complicated by [[Heart failure with reduced ejection fraction|heart failure with reduced ejection fraction (HFrEF)]].<ref name=":0" /> | ||
* Other [[Complication (medicine)|complications]] include: | * Other [[Complication (medicine)|complications]] include: | ||
** [[Left bundle branch block|Left bundle branch block (LBBB)]] | ** [[Left bundle branch block|Left bundle branch block (LBBB)]]<ref>{{Cite journal | ||
| author = [[Claudio Rapezzi]], [[Giampaolo Merlini]], [[Candida C. Quarta]], [[Letizia Riva]], [[Simone Longhi]], [[Ornella Leone]], [[Fabrizio Salvi]], [[Paolo Ciliberti]], [[Francesca Pastorelli]], [[Elena Biagini]], [[Fabio Coccolo]], [[Robin M. T. Cooke]], [[Letizia Bacchi-Reggiani]], [[Diego Sangiorgi]], [[Alessandra Ferlini]], [[Michele Cavo]], [[Elena Zamagni]], [[Maria Luisa Fonte]], [[Giovanni Palladini]], [[Francesco Salinaro]], [[Francesco Musca]], [[Laura Obici]], [[Angelo Branzi]] & [[Stefano Perlini]] | |||
| title = Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types | |||
| journal = [[Circulation]] | |||
| volume = 120 | |||
| issue = 13 | |||
| pages = 1203–1212 | |||
| year = 2009 | |||
| month = September | |||
| doi = 10.1161/CIRCULATIONAHA.108.843334 | |||
| pmid = 19752327 | |||
}}</ref> | |||
** [[Peripheral neuropathy]] | ** [[Peripheral neuropathy]] | ||
** [[Tendon]] [[rupture]] | ** [[Tendon]] [[rupture]] |
Revision as of 19:15, 17 December 2019
Wild-type (senile) amyloidosis Microchapters |
Differentiating Wild-type (senile) amyloidosis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Wild-type (senile) amyloidosis natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Wild-type (senile) amyloidosis natural history, complications and prognosis |
FDA on Wild-type (senile) amyloidosis natural history, complications and prognosis |
CDC on Wild-type (senile) amyloidosis natural history, complications and prognosis |
Wild-type (senile) amyloidosis natural history, complications and prognosis in the news |
Blogs on Wild-type (senile) amyloidosis natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Natural History, Complications, and Prognosis
Natural History
- In amyloidosis, insoluble fibrils of amyloid are deposited in the organs, causing organ dysfunction and eventually death.[1]
- Wild-type (senile) amyloidosis, as the name suggests, is a disease of the elderly.
- The clinical picture of the disease corresponds to the type of organ or organ system involved.
- It most commonly affects the heart and hence, clinical features pertaining to cardiac pathologies, dominate the clinical course of the disease.
- The deposition of transthyretin (TTR) in the heart causes it to start functionally failing.[2]
- The constellation of signs and symptoms of a TTR affected heart can mimic heart failure due to old age, and can thus mask the systemic involvement of wild-type (senile) amyloidosis.
- If left untreated, wild-type (senile) amyloidosis can lead to heart failure with reduced ejection fraction (HFrEF) and eventually death.[3]
Complications
- Wild-type (senile) amyloidosis is most commonly complicated by heart failure with reduced ejection fraction (HFrEF).[3]
- Other complications include:
Prognosis
References
- ↑ Baker KR, Rice L (2012). "The amyloidoses: clinical features, diagnosis and treatment". Methodist Debakey Cardiovasc J. 8 (3): 3–7. PMC 3487569. PMID 23227278.
- ↑ Belinda Ng, Lawreen H. Connors, Ravin Davidoff, Martha Skinner & Rodney H. Falk (2005). "Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis". Archives of internal medicine. 165 (12): 1425–1429. doi:10.1001/archinte.165.12.1425. PMID 15983293. Unknown parameter
|month=
ignored (help) - ↑ 3.0 3.1 Belinda Ng, Lawreen H. Connors, Ravin Davidoff, Martha Skinner & Rodney H. Falk (2005). "Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis". Archives of internal medicine. 165 (12): 1425–1429. doi:10.1001/archinte.165.12.1425. PMID 15983293. Unknown parameter
|month=
ignored (help) - ↑ Claudio Rapezzi, Giampaolo Merlini, Candida C. Quarta, Letizia Riva, Simone Longhi, Ornella Leone, Fabrizio Salvi, Paolo Ciliberti, Francesca Pastorelli, Elena Biagini, Fabio Coccolo, Robin M. T. Cooke, Letizia Bacchi-Reggiani, Diego Sangiorgi, Alessandra Ferlini, Michele Cavo, Elena Zamagni, Maria Luisa Fonte, Giovanni Palladini, Francesco Salinaro, Francesco Musca, Laura Obici, Angelo Branzi & Stefano Perlini (2009). "Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types". Circulation. 120 (13): 1203–1212. doi:10.1161/CIRCULATIONAHA.108.843334. PMID 19752327. Unknown parameter
|month=
ignored (help)